Efficacy and Safety in Imlifidase Desensitized Kidney Tx Patients, Including Two Non-Comparative Reference Cohorts
Status:
Recruiting
Trial end date:
2024-12-01
Target enrollment:
Participant gender:
Summary
An open-label post authorization efficacy and safety study evaluating graft failure-free
survival at 1-year in highly sensitized end-stage renal disease (ESRD) patients with positive
crossmatch (XM) against a deceased donor prior to desensitized with imlifidase and subsequent
kidney transplantation. Two non-comparative reference cohorts are included to assess the
impact of differences in post-transplantation management and outcome in less sensitized
patients.